abstract |
The present invention relates to the therapeutic use of molecules that bind to and neutralize IFN-γ in primates. More particularly, the present invention relates to the use of anti-primate IFN-γ antibodies for preventing or treating diseases where IFN-γ is pathogenic. Furthermore, the present invention relates to a pharmaceutical composition comprising an anti-primate IFN-γ antibody D9D10 for preventing or treating a pathological reaction caused by IFN-γ. |